A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18 (ROSSELLA)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04808505 |
Recruitment Status :
Recruiting
First Posted : March 22, 2021
Last Update Posted : May 6, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Glycogen Storage Disease Type II Infantile Onset | Biological: Cipaglucosidase alfa Drug: Miglustat | Phase 3 |
Expanded Access : An investigational treatment associated with this study is available outside the clinical trial. More info ...
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 36 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open-label Study to Evaluate the Safety, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Cipaglucosidase Alfa/Miglustat in Both ERT-experienced and ERT-naïve Pediatric Subjects With Infantile-onset Pompe Disease Aged 0 to < 18 Years |
Actual Study Start Date : | July 18, 2023 |
Estimated Primary Completion Date : | April 2027 |
Estimated Study Completion Date : | April 2027 |
Arm | Intervention/treatment |
---|---|
Experimental: Cohort 1: Cipaglucosidase Alfa/Miglustat in ERT-experienced pediatric IOPD subjects
Pediatric IOPD subjects 6 months to <18 years experiencing clinical decline
|
Biological: Cipaglucosidase alfa
Sterile lyophilized powder intravenous (IV) infusion
Other Name: ATB200 Drug: Miglustat 65 mg oral capsules
Other Name: AT2221 |
Experimental: Cohort 2: Cipaglucosidase Alfa/Miglustat in ERT-naïve pediatric IOPD subjects
Pediatric IOPD subjects <6 months
|
Biological: Cipaglucosidase alfa
Sterile lyophilized powder intravenous (IV) infusion
Other Name: ATB200 Drug: Miglustat 65 mg oral capsules
Other Name: AT2221 |
- Proportion of subjects with infusion-associated reactions (IARs) [ Time Frame: 104 weeks ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | up to 17 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Cohort 1:
- Male or female subjects who are aged 6 months to < 18 years on Day 1
- Subject must have documentation of IOPD genotype
- Subject must have had hypertrophic cardiomyopathy at the time of diagnosis
- Subject must have received ERT for at least 6 months immediately before enrollment. For subjects whose ERT dosage has been modified, the subject must have been on the modified dosage and regimen for at least 3 months before enrollment
- Subjects aged ≥ 12 to < 18 years must perform one valid 6-minute walk test (6MWT) (≥ 75 meters) at screening; Subjects aged ≥ 5 to < 12 years must perform one valid 6MWT (≥ 40 meters) at screening; Subjects aged 18 months to < 5 years must be ambulatory and assessed to be likely to be able to perform 6MWT (≥ 40 meters) when they turn 5 years old
- Subjects must have experienced a clinical decline on their current rhGAA dose and frequency
Cohort 2:
- Male or female subjects who are aged 0 to <6 months at Day 1
- Subject must have documentation of IOPD genotype
- Subject must have had hypertrophic cardiomyopathy at the time of diagnosis
- Subject is ERT-naïve
Long-term Extension (Cohort 1 or Cohort 2):
1. Subject must have, in the opinion of the investigator, benefited from therapy with cipaglucosidase alfa/miglustat during the 104-week primary treatment period with no significant safety concerns.
Exclusion Criteria:
Cohort 1 and Cohort 2, unless specified
- Subject requires invasive ventilation (eg, tracheostomy)
- Subject is CRIM negative and has not received prophylactic immunomodulation (Cohort 1); Subject is CRIM negative and will not be receiving prophylactic immunomodulation (Cohort 2)
- Subject has a history of life-threatening IARs/hypersensitivity (eg, anaphylaxis and severe cutaneous reactions) to ERT (eg, alglucosidase alfa, cipaglucosidase alfa, miglustat) or other iminosugars, or to any of the excipients, where rechallenge was unsuccessful
- Subject has prior history of illness or condition known to affect motor function
- Female subject is pregnant (or intends to get pregnant) or breastfeeding at screening (Cohort 1)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04808505
Contact: For Site | 215-921-7600 | PompeSiteInfo@amicusrx.com | |
Contact: For Patient | 215-921-7600 | patientadvocacy@amicusrx.com |
United States, Florida | |
University of Florida Clinical Research Center | Recruiting |
Gainesville, Florida, United States, 32610 | |
United States, Georgia | |
The Emory Clinic | Recruiting |
Atlanta, Georgia, United States, 30322 | |
United States, North Carolina | |
Duke University Early Phase Research Unit | Recruiting |
Durham, North Carolina, United States, 27710 | |
United States, Utah | |
University of Utah, Clinical and Translational Sciences Institute | Recruiting |
Salt Lake City, Utah, United States, 84108 | |
France | |
Hôpital Raymond Poincaré, Neurologie et réanimation pédiatriques | Not yet recruiting |
Garches, France, 92380 | |
Germany | |
Universitätsklinikum Gießen und Marburg GmbH, Zentrum fur Kinderheilkunde und Jugendmedizin Abteilung fur Kinderneurologic, Sozialpadiatric und Epileptologie | Not yet recruiting |
Gießen, Germany, 35392 | |
SphinCS GmbH | Not yet recruiting |
Hochheim, Germany, 65239 | |
Universitätsklinikum Münster Klinik für Kinder- und Jugendmedizin Albert-Schweitzer-Campus 1 | Not yet recruiting |
Münster, Germany, 48149 | |
Italy | |
AOU Federico II | Not yet recruiting |
Naples, Italy, 80131 | |
Azienda Ospedale Inherited Metabolic Disease Department | Not yet recruiting |
Padova, Italy, 35128 | |
Taiwan | |
National Taiwan University Hospital | Withdrawn |
Taipei, Taiwan, 100 | |
United Kingdom | |
Great Ormond Street Hospital for Children NHS Foundation Trust | Not yet recruiting |
London, United Kingdom, WC1N3JH |
Responsible Party: | Amicus Therapeutics |
ClinicalTrials.gov Identifier: | NCT04808505 |
Other Study ID Numbers: |
ATB200-08 |
First Posted: | March 22, 2021 Key Record Dates |
Last Update Posted: | May 6, 2024 |
Last Verified: | August 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Glycogen Storage Disease Type II Glycogen Storage Disease Carbohydrate Metabolism, Inborn Errors Metabolism, Inborn Errors Genetic Diseases, Inborn Metabolic Diseases Lysosomal Storage Diseases, Nervous System Brain Diseases, Metabolic, Inborn Brain Diseases, Metabolic Brain Diseases Central Nervous System Diseases Nervous System Diseases |
Lysosomal Storage Diseases Miglustat Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Glycoside Hydrolase Inhibitors Hypoglycemic Agents Physiological Effects of Drugs |